TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07761429: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study Evaluating the Safety and Efficacy of F520 Combined With Paclitaxel Plus Carboplatin as First-line Treatment for Cancer of Unknown Primary

Sponsor: Shandong New Time Pharmaceutical Co., LTD · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 402 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT07761429 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07761429 Rescue Dossier →